



Heart Failure Dashboard

Catholic Health

	Data Through	Current Month	Q3 2026	YTD 2026	2025	"Reference values"
Discharge Medications in 4 GDMT Classes						NEJM, ESHF, 11/20-5/22, 2/3 Class III or IV AF ablation in CHF study
MRA (spironolactone) (%)	Aug-26	25.0%	26.6%	21.4%	20.6%	50%
SGLT2i (%)	Aug-26	41.3%	38.6%	34.5%	32.7%	25%
RAS Blockers ACEI/ARB/ARNI - <u>any</u> dose (%)	Aug-26	28.8%	27.2%	20.4%	20.2%	38% ACE/ARB 63% ARNI
Beta Blocker - <u>any</u> dose (%)	Aug-26	43.8%	43.7%	40.1%	37.7%	95%
Patient Type						
HFpEF (EF>50%)	Aug-26	47.5%	47.5%	47.3%	44.5%	
LOS						
Average Length of Stay - days	Aug-26	4.4	4.5	5.5	5.8	
Readmissions						
All Cause Readmissions (%)	Aug-26	16.7%	15.4%	15.0%	14.6%	

Updated: 9/9/2026

100% on RAS blockers